CN112584900B - 精氨酸酶抑制剂及其使用方法 - Google Patents

精氨酸酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN112584900B
CN112584900B CN201980055111.3A CN201980055111A CN112584900B CN 112584900 B CN112584900 B CN 112584900B CN 201980055111 A CN201980055111 A CN 201980055111A CN 112584900 B CN112584900 B CN 112584900B
Authority
CN
China
Prior art keywords
aza
oxa
hydroxy
dodecane
methylbutanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980055111.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112584900A (zh
Inventor
吴德冬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN112584900A publication Critical patent/CN112584900A/zh
Application granted granted Critical
Publication of CN112584900B publication Critical patent/CN112584900B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980055111.3A 2018-08-22 2019-08-21 精氨酸酶抑制剂及其使用方法 Active CN112584900B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721113P 2018-08-22 2018-08-22
US62/721113 2018-08-22
PCT/EP2019/072341 WO2020038983A1 (en) 2018-08-22 2019-08-21 Arginase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
CN112584900A CN112584900A (zh) 2021-03-30
CN112584900B true CN112584900B (zh) 2025-07-15

Family

ID=67742403

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980055111.3A Active CN112584900B (zh) 2018-08-22 2019-08-21 精氨酸酶抑制剂及其使用方法

Country Status (25)

Country Link
US (1) US11952392B2 (enExample)
EP (2) EP4371614A3 (enExample)
JP (1) JP7441210B2 (enExample)
KR (1) KR102668252B1 (enExample)
CN (1) CN112584900B (enExample)
AU (1) AU2019323663B2 (enExample)
CA (1) CA3109100A1 (enExample)
CL (1) CL2021000430A1 (enExample)
DK (1) DK3840837T3 (enExample)
EA (1) EA202190532A1 (enExample)
ES (1) ES2980252T3 (enExample)
FI (1) FI3840837T3 (enExample)
HR (1) HRP20240694T1 (enExample)
HU (1) HUE066903T2 (enExample)
IL (1) IL280924B2 (enExample)
LT (1) LT3840837T (enExample)
MA (1) MA53427B1 (enExample)
MX (1) MX2021002042A (enExample)
PL (1) PL3840837T3 (enExample)
PT (1) PT3840837T (enExample)
RS (1) RS65608B1 (enExample)
SG (1) SG11202101618PA (enExample)
SI (1) SI3840837T1 (enExample)
SM (1) SMT202400221T1 (enExample)
WO (1) WO2020038983A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MY206577A (en) * 2019-02-08 2024-12-24 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP4239652A4 (en) 2020-12-25 2024-06-05 Sumitomo Riko Company Limited Electrically conductive composition, sheet-form flexible electrode using same, and method for producing said electrode

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068830A (zh) * 2010-04-22 2013-04-24 马尔斯公司 精氨酸酶抑制剂及其治疗应用
CN107921051A (zh) * 2015-06-23 2018-04-17 卡里塞拉生物科学股份公司 抑制精氨酸酶活性的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068830A (zh) * 2010-04-22 2013-04-24 马尔斯公司 精氨酸酶抑制剂及其治疗应用
CN107921051A (zh) * 2015-06-23 2018-04-17 卡里塞拉生物科学股份公司 抑制精氨酸酶活性的组合物和方法

Also Published As

Publication number Publication date
EP3840837B1 (en) 2024-03-20
SMT202400221T1 (it) 2024-07-09
JP7441210B2 (ja) 2024-02-29
CA3109100A1 (en) 2020-02-27
EP4371614A2 (en) 2024-05-22
KR102668252B1 (ko) 2024-05-21
US20210332068A1 (en) 2021-10-28
PL3840837T3 (pl) 2024-08-19
MA53427B1 (fr) 2024-06-28
MX2021002042A (es) 2021-04-28
WO2020038983A1 (en) 2020-02-27
HRP20240694T1 (hr) 2024-08-16
KR20210049120A (ko) 2021-05-04
US11952392B2 (en) 2024-04-09
RS65608B1 (sr) 2024-07-31
IL280924B2 (en) 2024-10-01
HUE066903T2 (hu) 2024-09-28
IL280924B1 (en) 2024-06-01
SI3840837T1 (sl) 2024-07-31
EP3840837A1 (en) 2021-06-30
MA53427A (fr) 2021-12-01
DK3840837T3 (da) 2024-06-10
JP2021535111A (ja) 2021-12-16
EA202190532A1 (ru) 2021-07-08
AU2019323663B2 (en) 2022-07-14
IL280924A (en) 2021-04-29
SG11202101618PA (en) 2021-03-30
ES2980252T3 (es) 2024-09-30
LT3840837T (lt) 2024-06-10
AU2019323663A1 (en) 2021-04-08
FI3840837T3 (fi) 2024-06-03
EP4371614A3 (en) 2025-09-24
CL2021000430A1 (es) 2021-09-03
PT3840837T (pt) 2024-06-14
CN112584900A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
JP7441210B2 (ja) アルギナーゼインヒビタ及びその使用方法
JP7699171B2 (ja) アルギナーゼインヒビタ及びその使用方法
HK40042067A (en) Arginase inhibitors and methods of use thereof
HK40110939A (en) Arginase inhibitors and methods of use thereof
HK40042067B (en) Arginase inhibitors and methods of use thereof
HK40055578A (en) Arginase inhibitors and methods of use thereof
HK40055578B (en) Arginase inhibitors and methods of use thereof
EA042333B1 (ru) Ингибиторы аргиназы и способы их применения
KR102885194B1 (ko) 아르기나제 저해제 및 이의 사용 방법
EA042598B1 (ru) Ингибиторы аргиназы и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042067

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant